Melanotan 1

Melanotan 1, known generically as afamelanotide, is a synthetic analog of alpha-melanocyte stimulating hormone (alpha-MSH). It was developed at the University of Arizona in the 1980s as part of a research program aimed at creating a pharmacological tanning agent that could reduce UV-induced skin damage. The peptide differs from native alpha-MSH by two structural modifications: a substitution of norleucine for methionine at position 4, and a D-isomer phenylalanine at position 7. These changes substantially increase receptor binding affinity and metabolic stability, giving afamelanotide a much longer effective half-life than the endogenous hormone.

Melanotan 1 acts as a selective agonist at the melanocortin 1 receptor (MC1R), which is expressed on the surface of melanocytes, the pigment-producing cells of the skin. MC1R activation triggers a rise in intracellular cyclic AMP (cAMP) and subsequent activation of cAMP-dependent protein kinase A (PKA). This cascade upregulates the transcription factor MITF and increases the expression and activity of melanogenic enzymes, particularly tyrosinase. The net effect is a shift in melanin production toward eumelanin, the brown-black pigment that provides the most photoprotective qualities, as opposed to phaeomelanin, the red-yellow pigment associated with fair, UV-sensitive skin. Critically, this pigmentation occurs with or without UV exposure, though ultraviolet light acts synergistically to amplify the tanning response.

The clinical development of afamelanotide is among the most complete of any research peptide. Phase I studies established safety at subcutaneous doses of 0.08-0.16 mg/kg. Phase II and III trials demonstrated both efficacy and a defined regulatory use. In tanning research, studies published in JAMA Dermatology found that subjects receiving Melanotan 1 combined with UV-B light had 47% fewer sunburn cells and significantly enhanced tanning compared to UV-B alone. The compound received its first regulatory approval from the Italian Medicines Agency (AIFA) in May 2010, followed by European Medicines Agency (EMA) approval in January 2015 under the brand name Scenesse, specifically indicated for prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe pain upon sun exposure. The U.S. FDA approved Scenesse in October 2019 for the same indication, making afamelanotide one of the few peptides with a genuine FDA approval for a specific medical condition.

The EPP indication is distinct from cosmetic tanning use. People with EPP cannot tolerate any sunlight exposure without pain due to accumulation of protoporphyrin IX in the skin. Afamelanotide dramatically increases their pain-free light exposure time. The approved delivery method for EPP treatment is a bioresorbable implant (16 mg) placed subcutaneously, not self-injection. Research-grade injectable Melanotan 1 sold as a peptide is chemically identical but its use for cosmetic tanning represents off-label, unapproved self-administration outside the controlled clinical framework.